Financial Gravity Asset Management’s TG Therapeutics TGTX Stock Holding History

Financial Gravity Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-20	Closed	-$312	–	2343
2024 Q1	$312	Buy	20 +14	+233%	+$223	﹤0.01%	1523
2023 Q4	$83	Buy	6 +3	+100%	+$35	﹤0.01%	1276
2023 Q3	$25	Sell	3 -22	-88%	-$307	﹤0.01%	1118
2023 Q2	$152	Buy	+25	New	+$646	﹤0.01%	1229
2023 Q1	–	Sell	-12	Closed	-$10	–	1629
2022 Q4	$10	Buy	+12	New	+$87	﹤0.01%	1366
2021 Q2	–	Sell	-1	Closed	-$29	–	1019
2021 Q1	$29	Buy	+1	New	+$48	﹤0.01%	621
2020 Q2	–	Sell	-41	Closed	-$400	–	813
2020 Q1	$400	Hold	41	–	–	﹤0.01%	591
2019 Q4	$11K	Hold	41	–	–	0.01%	1182
2019 Q3	$0	Hold	41	–	–	﹤0.01%	1545
2019 Q2	$0	Hold	41	–	–	﹤0.01%	1654
2019 Q1	$0	Buy	+41	New	+$222	﹤0.01%	1540
2018 Q3	$0	Buy	+41	New	+$468	﹤0.01%	1612

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Financial Gravity Asset Management's TGTX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of TG Therapeutics (TGTX) in Q2 2024, closing a stake of 20 shares — an estimated $312 sold.

Financial Gravity Asset Management first reported a position in TGTX in Q3 2018 and held it in 12 quarters. The position peaked at $11K in Q4 2019. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.

Financial Gravity Asset Management reported no remaining TG Therapeutics position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 20 TG Therapeutics shares in Q2 2024, an estimated $312.
Financial Gravity Asset Management first reported a position in TG Therapeutics in Q3 2018 and held it in 12 quarters.
Financial Gravity Asset Management's TG Therapeutics position peaked at $11K in Q4 2019.
259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.